Apremilast for oral ulcers associated with active Behcet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial

Hatemi G., Mahr A., Takeno M., Kim D. Y., Saadoun D., DİRESKENELİ R. H., ...More

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.39, no.5, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 5
  • Publication Date: 2021
  • Journal Name: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Keywords: Behcet's syndrome, long-term treatment, phosphodiesterase 4 inhibitor, quality of life, oral ulcers, PHOSPHODIESTERASE-4 INHIBITOR, PSORIATIC-ARTHRITIS
  • Marmara University Affiliated: Yes

Abstract

Objective. This study assessed the efficacy and safety of apremilast for the oral ulcers associated with Behcet's syndrome (BS) up to 64 weeks.